Insight Molecular Diagnostics Inc. — Director's Dealing 2022

Dec 28, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-12-23

Reporting Person: Arno Andrew (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-23	Common Stock, no par value	P	250000	$0.3515	Acquired	532049	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	15000	Indirect
Common Stock, no par value	15000	Indirect

Footnotes

F1: The price of $0.3515 per share represents a weighted average of prices ranging from $0.29 to $0.4284 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: The shares of common stock are held by JBA Investments LLC. The Reporting Person is the Manager of JBA Investments LLC and in such capacity has the right to vote and dispose of the securities held by such entity.

F3: The shares of common stock are held by MJA Investments LLC. The Reporting Person is the Manager of MJA Investments LLC and in such capacity has the right to vote and dispose of the securities held by such entity.